Frazier Life Sciences Adds Industry Veteran and Serial Dealmaker, Adam Simpson, to Company Creation Team
Frazier Life Sciences (FLS) has announced the addition of Adam Simpson as Venture Partner in its Company Creation team. Simpson, an industry veteran with 25 years of experience, has helped build 11 companies that have been acquired or gone public. He most recently served as CEO of Icosavax (Nasdaq: ICVX), leading it through its IPO and subsequent acquisition by AstraZeneca. Simpson's expertise includes team building, advancing novel technologies through clinical proof-of-concept, and leading significant fundraising, partnerships, and acquisitions. At FLS, he will support new company innovation and portfolio company growth, leveraging his financial, operational, and emerging company knowledge.
Frazier Life Sciences (FLS) ha annunciato l'aggiunta di Adam Simpson come Partner di Venture nel suo team di Creazione Aziendale. Simpson, un veterano del settore con 25 anni di esperienza, ha contribuito alla creazione di 11 aziende che sono state acquisite o sono diventate pubbliche. Recentemente ha ricoperto il ruolo di CEO di Icosavax (Nasdaq: ICVX), guidandola attraverso l'IPO e la successiva acquisizione da parte di AstraZeneca. L'expertise di Simpson include la costruzione di team, l'avanzamento di tecnologie innovative attraverso prove cliniche di concetto e la gestione di significativi fundraising, partnership e acquisizioni. Presso FLS, supporterà l'innovazione delle nuove imprese e la crescita delle aziende nel portafoglio, sfruttando la sua conoscenza in ambito finanziario, operativo e delle aziende emergenti.
Frazier Life Sciences (FLS) ha anunciado la incorporación de Adam Simpson como Socio de Capital de Riesgo en su equipo de Creación de Empresas. Simpson, un veterano de la industria con 25 años de experiencia, ha ayudado a construir 11 empresas que han sido adquiridas o que se han hecho públicas. Recientemente, se desempeñó como CEO de Icosavax (Nasdaq: ICVX), liderando su OPI y la posterior adquisición por parte de AstraZeneca. La experiencia de Simpson incluye la formación de equipos, el avance de tecnologías novedosas a través de pruebas clínicas de concepto, y la dirección de importantes financiamientos, asociaciones y adquisiciones. En FLS, apoyará la innovación de nuevas empresas y el crecimiento de las empresas del portafolio, aprovechando su conocimiento en finanzas, operaciones y empresas emergentes.
프레이저 라이프 사이언스(FLS)는 아담 심슨을 회사 창출 팀의 벤처 파트너로 추가했다고 발표했습니다. 심슨은 25년 경력을 가진 업계 베테랑으로, 11개의 기업을 설립하여 인수되거나 상장되었습니다. 최근에는 아이코사박스 (Nasdaq: ICVX)의 CEO로 재직하며, 상장 및 이후 아스트라제네카에 인수되는 과정을 이끌었습니다. 심슨의 전문 분야는 팀 빌딩, 혁신 기술 발전을 위한 임상 개념 증명, 그리고 중요한 자금 조달, 파트너십 및 인수을 주도하는 것입니다. FLS에서는 새로운 기업 혁신과 포트폴리오 기업의 성장을 지원하며 재무, 운영 및 신생 기업에 대한 지식을 활용할 것입니다.
Frazier Life Sciences (FLS) a annoncé l'ajout de Adam Simpson en tant que Partenaire de Capital Risque dans son équipe de Création d'Entreprises. Simpson, un vétéran de l'industrie avec 25 ans d'expérience, a contribué à la création de 11 entreprises qui ont été acquises ou sont devenues publiques. Il a récemment été PDG d'Icosavax (Nasdaq: ICVX), la guidant à travers son introduction en bourse et la ré acquisition ultérieure par AstraZeneca. L'expertise de Simpson comprend la constitution d'équipes, l'avancement de technologies novatrices à travers des preuves de concept cliniques, ainsi que la direction de financements, de partenariats et d'acquisitions significatifs. Chez FLS, il soutiendra l'innovation des nouvelles entreprises et la croissance des entreprises du portefeuille, en utilisant ses connaissances financières, opérationnelles et des entreprises émergentes.
Frazier Life Sciences (FLS) hat die Ernennung von Adam Simpson zum Venture Partner in seinem Team für Unternehmensgründungen bekannt gegeben. Simpson, ein Branchenveteran mit 25 Jahren Erfahrung, hat beim Aufbau von 11 Unternehmen geholfen, die übernommen oder an die Börse gebracht wurden. Zuletzt war er CEO von Icosavax (Nasdaq: ICVX) und leitete das Unternehmen durch den Börsengang und die anschließende Übernahme durch AstraZeneca. Simpsons Expertise umfasst Teambildung, die Förderung neuer Technologien durch klinische Machbarkeitsnachweise sowie die Leitung bedeutender Finanzierungs-, Partnerschafts- und Akquisitionsprojekte. Bei FLS wird er die Innovation neuer Unternehmen und das Wachstum des Portfoliounternehmens unterstützen und dabei sein Wissen in den Bereichen Finanzen, Betrieb und aufstrebende Unternehmen nutzen.
- Addition of experienced industry veteran Adam Simpson to the Company Creation team
- Simpson's track record of building 11 successful life sciences companies
- Expertise in advancing novel technologies through clinical proof-of-concept
- Strong experience in fundraising, partnerships, and acquisitions
- Potential for enhanced portfolio company growth and innovation at Frazier Life Sciences
- None.
Insights
The addition of Adam Simpson to Frazier Life Sciences' Company Creation team is a neutral development for the firm. While Simpson's extensive experience in building successful biotech companies is impressive, it's important to note that this type of personnel change doesn't directly impact the firm's financial performance or investment portfolio in the short term. Long-term implications could be positive if Simpson's expertise leads to more successful company creations and exits, but this remains to be seen. Investors should monitor future announcements for any notable company formations or deals that may result from this hire.
From a financial perspective, the key metrics to watch will be the performance of new portfolio companies and any exits (acquisitions or IPOs) that occur under Simpson's guidance. His track record suggests potential for value creation, but it's important to remember that past performance doesn't guarantee future results in the volatile biotech sector.
Adam Simpson's appointment to Frazier Life Sciences' team is a strategic move that could enhance the firm's company creation capabilities. His experience with 11 companies that have been acquired or gone public is particularly noteworthy in the biotech industry, where successful exits are crucial. Simpson's expertise in advancing novel technologies through clinical proof-of-concept aligns well with FLS's focus on innovative biopharmaceuticals.
His recent success with Icosavax, developing a virus-like particle platform for respiratory diseases, demonstrates his ability to navigate cutting-edge biotech developments. This expertise could be valuable for FLS in identifying and developing promising new technologies. However, the biotech landscape is rapidly evolving and past successes don't guarantee future performance. Investors should watch for any new company formations or technology platforms that emerge from this collaboration.
Simpson has helped build 11 companies that have been acquired or gone public, most recently serving as CEO of Icosavax
Over the last 25 years, Simpson has served as a co-founder, executive and/or board member of 11 life sciences companies that have either been acquired or gone public. His broad experience from these roles focuses on team building, advancing novel technologies through clinical proof-of-concept and leading significant fundraising, partnerships and acquisitions. He will leverage his financial, operational and emerging company knowledge to support new company innovation and portfolio company growth at FLS. Simpson will be based in Frazier Life Sciences’
“Adam has a strong track record of successfully building companies that advance technologies through proof of concept and achieve meaningful exits,” said Patrick Heron, Managing Partner at FLS. “We look forward to having his strong biopharmaceutical operational and business development experience on our team as we continue to develop new and innovative companies.”
Simpson most recently served as Co-Founder, CEO and Board Member at Icosavax (Nasdaq: ICVX) through its IPO and subsequent acquisition by AstraZeneca. He built a team that leveraged a virus-like particle platform to advance multiple product candidates into the clinic for respiratory diseases, including an RSV/hMPV combination vaccine through Phase 3 readiness. Earlier in his career, Simpson was CEO and served on the board of PvP Biologics, where he advanced an oral enzyme to treat celiac disease from preclinical candidate into the clinic and led the company's acquisition by Takeda. He also served as Co-Founder and CBO of Meritage Pharma until its staged sale to Shire, which led to the first FDA-approved oral treatment for eosinophilic esophagitis. Simpson began his career as an attorney at Latham & Watkins LLP, focusing on life sciences transactions.
“Joining the team at Frazier Life Sciences gives me the opportunity to bring my years of operational and business development experience to support the creation and growth of multiple new companies on the West Coast,” said Simpson. “I’m excited to work together with the team at Frazier Life Sciences to help our portfolio companies have the necessary team, resources and foundation from the start.”
“With the addition of Adam to the team, we are excited to continue our growth in San Diego,” said Dan Estes, General Partner at FLS. “We look forward to working with Adam to create and grow potentially world class biopharmaceutical companies, bringing novel medicines to patients.”
About Frazier Life Sciences:
Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over
Venture Partners are employed by a subsidiary of FLS, provide advisory and consulting service to FLS and often serve in operational positions within FLS portfolio companies or search companies (“SearchCos”). Venture Partners are permitted to receive a material equity position in a portfolio company or SearchCo, and any compensation paid to such Venture Partners is borne directly or indirectly by the portfolio companies, SearchCos or the applicable FLS fund and will not offset any management fees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919823575/en/
For media inquiries, please contact:
Ailsa Dalgliesh, Ph.D.
Head of Investor Relations
ailsa@frazierls.com
Source: Frazier Life Sciences
FAQ
What is Adam Simpson's new role at Frazier Life Sciences?
How many companies has Adam Simpson helped build that were acquired or went public?
What was Adam Simpson's most recent position before joining Frazier Life Sciences?
What specific expertise does Adam Simpson bring to Frazier Life Sciences?
